TY - JUR A2 - PELTEKIAN，KEVORK M. AU - Zhu，Dong-Mei Au - 谢，景奥烨，春艳，春谦，梅云奥薛，元PY - 2020年 - 2020/12 /18吨 - 肝细胞癌风险患者患者患者患者患者患者患者患者有关的失代偿的肝硬化和长期抗病毒治疗SP - 8871024 VL - 2020 AB - 背景。本研究旨在评估乙型肝炎病毒（HBV）相关DC患者HCC开发的危险因素，以及接受长期抗病毒治疗的人。 方法。收集了308例HBV相关的DC患者和长期抗病毒治疗的数据并回顾性审查。COX回归分析用于分析HCC开发的独立风险因素。 结果。分析了129名明确记录患者的数据。中位后续时间为5年（范围，1至8年）。在随访结束时，41名（31.8％）患者开发了HCC，从DC诊断到接受抗病毒治疗的HCC发病率的时间为4.4岁（范围，1-7岁）。HCC的发病率高于女性（11/51,21.6％）（11/51,21.6％）（ P.  = 0.04). Patients who developed HCC were significantly older than those who did not develop HCC ( P.  < 0.01). The incidence of HCC in patients receiving nucleoside analogues, nucleotide analogues, and combination therapy was 34.7%, 38.1%, and 33.3%, respectively, and the difference showed no significant differences ( P.  = 0.95). Multivariate Cox regression analysis demonstrated that male gender and age ≥50 years are independent risk factors of HCC development (OR = 2.987 and 2.408; 95% CI (1.301–6.858) and (1.126–5.149); P.  = 0.01 and 0.02, respectively). 结论。HBV相关DC患者的HCC风险仍然很高，尤其是≥50岁的男性。SN - 2291-2789 UR - https://doi.org/10.1155/2020/8871024 Do - 10.1155 / 2020/8871024 JF - 加拿大胃肠学和肝脏学杂志PB - Hindawi Kw - ER -